Sidley represented Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, in the acquisition of Denali Medpharma, a leading China-based bioanalytical CRO. Resolian has bioanalysis laboratory operations in the U.S., UK, Australia, and China. The multidisciplinary Sidley team was led by partner Ruchun Ji. The […]
The post Sidley Represented Resolian in its Acquisition of China-Based Bioanalytical CRO Denali Medpharma appeared first on Legal Desire Media and Insights.